Oxycodonhydrochlorid ”Lannacher”, depot tablets ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
298Hereditary pancreatitis1

298. Hereditary pancreatitis


Clinical trials : 95 Drugs : 148 - (DrugBank : 51) / Drug target genes : 53 - Drug target pathways : 142
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2017-000732-34-DK
(EUCTR)
21/06/201725/04/2017Drug Release and Absorption from Controlled Release Formulations in Patients with Gastrointestinal Dysfunctions.Oral Controlled Release Formulations to Patients with Gastrointestinal Dysfunction – Is the Release of Drug and the Absorption Impaired? - ABOXY Healthy (pain) and patients (pain).
MedDRA version: 20.1;Level: LLT;Classification code 10009093;Term: Chronic pancreatitis;System Organ Class: 100000004856
MedDRA version: 20.0;Classification code 10012594;Term: Diabetes;System Organ Class: 100000004861
MedDRA version: 20.0;Classification code 10048516;Term: Gastrointestinal disorder (NOS);Classification code 10050554;Term: Gastric bypass NOS;System Organ Class: 100000004865 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Oxynorm
Product Name: Oxynorm
INN or Proposed INN: Oxycodone
Other descriptive name: OXYCODONE
Trade Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets
Product Name: Oxycodonhydrochlorid ”Lannacher”, depot tablets
INN or Proposed INN: Oxycodone
Other descriptive name: OXYCODONE HYDROCHLORIDE
Trade Name: Oxycodone Depot ”Sandoz”, depot tablets
Product Name: Oxycodone Depot ”Sandoz”, depot tablets
INN or Proposed INN: Oxycodone
Other descriptive name: OXYCODONE HYDROCHLORIDE
Mech-Sense, Dept. Gastroenterology & Hepatology, Aalborg University HospitalNULLNot Recruiting Female: yes
Male: yes
135 Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesDenmark